• 1
    Schuna AA. Update on treatment of rheumatoid arthritis. J Am Pharm Assoc (Wash) 1998; 38: 72835.
  • 2
    Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16: 58591.
  • 3
    Mottonen T. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988; 47: 64853.
  • 4
    Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol 1994; 21: 180813.
  • 5
    Van der Heijde DMFM, van Leeuwen MA, van Riel PLCM, Koster AM, van 't Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35: 2634.
  • 6
    Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 30515.
  • 7
    Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88: 144551.
  • 8
    Conti P. Interleukin-1 (IL-1) and interleukin-1 receptor antagonist (IL-1ra). Ann Med Interne (Paris) 1991; 142: 5215.
  • 9
    Elliott MJ, Maini RN. Anti-cytokine therapy in rheumatoid arthritis [review]. Baillieres Clin Rheumatol 1995; 9: 63352.
  • 10
    Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis [review]. Eur J Radiol 1998; 27 Suppl 1: S1824.
  • 11
    Rooney M, Symons JA, Duff GW. Interleukin 1 beta in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol Int 1990; 10: 2179.
  • 12
    Ruschen S, Stellberg W, Warnatz H. Kinetics of cytokine secretion by mononuclear cells of the blood from rheumatoid arthritis patients are different from those of healthy controls. Clin Exp Immunol 1992; 89: 327.
  • 13
    Eastgate JA, Symons JA, Wood NC, Grinlinton FM, di Giovine FS, Duff GW. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 2: 7069.
  • 14
    Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998; 16: 2755.
  • 15
    Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991; 266: 103316.
  • 16
    McIntyre KW, Stepan GJ, Kolinsky KD, Benjamin WR, Plocinski JM, Kaffka KL, et al. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med 1991; 173: 9319.
  • 17
    Firestein GS, Berger AE, Tracey DE, Chosay JG, Chapman DL, Paine MM, et al. IL-1 receptor antagonist protein production and gene expression in rheumatoid arthritis and osteoarthritis synovium. J Immunol 1992; 149: 105462.
  • 18
    Dinarello CA, Moldawer LL. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis: a primer for clinicians. 2nd ed. Thousand Oaks (CA): Amgen; 2000.
  • 19
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 20
    Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol 1977; 18: 48191.
  • 21
    Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196204.
  • 22
    Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498502.
  • 23
    Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 10019.
  • 24
    Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 2539.
  • 25
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti–tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 155263.
  • 26
    Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor–Fc fusion protein. N Engl J Med 1997; 337: 1417.
  • 27
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 28
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 29
    Felson DT, Anderson JJ, Lange MLM, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures rather than twenty percent? Arthritis Rheum 1998; 41: 156470.
  • 30
    Fries JF, Spitz PW, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 31
    Roos H, Karlsson R, Nilshans H, Persson A. Thermodynamic analysis of protein interactions with biosensor technology. J Mol Recognit 1998; 11: 20410.
  • 32
    Agresti A, Coull BA. Order-restricted tests for stratified comparisons of binomial proportions. Biometrics 1996; 52: 110311.
  • 33
    Weller EA, Ryan LM. Testing for trend with count data. Biometrics 1998; 54: 76273.
  • 34
    Mahrer JM, Magel RC. A comparison of tests for the k-sample, non-decreasing alternative. Stat Med 1995; 14: 86371.
  • 35
    Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data [review]. Stat Med 1997; 16: 234980.
  • 36
    Franklin HR, Simonetti GP, Dubbelman AC, Bokkel Huinink WW, Taal BG, Wigbout G, et al. Toxicity grading systems: a comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol 1994; 5: 1137.
  • 37
    Nuki G, Rozman B, Pavelka K, Emery P, Lookabaugh J, Musikic P. Interleukin-1 receptor antagonist continues to demonstrate clinical improvement in rheumatoid arthritis [abstract]. Arthritis Rheum 1997; 40 Suppl 9: S224.
  • 38
    Genant HK, Bresnihan B, Ng E, Robbins S, Newmark RD, McCabe DP. Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the second 6 months of treatment for patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S288.
  • 39
    Pincus T, Marcum SB, Callahan LF, Adams RF, Barber J, Barth WF, et al. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal antiinflammatory drugs. J Rheumatol 1992; 19: 187484.
  • 40
    Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 65565.
  • 41
    Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. the European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 25966.
  • 42
    Strand V, Cohen S, Schiff M, Weaver A. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 254250.
  • 43
    Furst DE. The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis [review]. Clin Exp Rheumatol 1999; 17: 3940.
  • 44
    Pincus T. Combination therapy for rheumatoid arthritis with methotrexate and cyclosporine [review]. Zeitschrift fur Rheumatologie 1998; 57: 346.
  • 45
    Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 55760.
  • 46
    Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994; 120: 2634.
  • 47
    Singh G, Terry R, Ramey D, Wolfe F, Fries J. Long-term medical costs and outcomes are significantly associated with early changes in disability in rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39 Suppl 9: S318.
  • 48
    Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, the IL-1Ra Arthritis Study Group. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1092101.